New filings for alogliptin diabetes combination uses in Japan
This article was originally published in Scrip
Takeda has filed for the approval in Japan of its DPP-4 inhibitor alogliptin for use in combination with either sulphonylurea or biguanide antidiabetic drugs.
You may also be interested in...
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.
Full, planned acquisition of Tokyo-based operation will give US biotech giant a firmer foothold in key market and new platform for Otezla growth.